Clayton-Chubb Daniel, Majeed Ammar, Kemp William W, Yu Chenglong, Lange Peter W, Fitzpatrick Jessica A, Woods Robyn L, Tonkin Andrew M, Chan Andrew T, Nelson Mark R, Ryan Joanne, Hodge Alexander D, Lubel John S, Schneider Hans G, McNeil John J, Roberts Stuart K
Department of Gastroenterology, Alfred Health, Melbourne 3004, Australia.
Department of Medicine, School of Translational Medicine, Monash University, Melbourne 3004, Australia.
Biomedicines. 2025 Aug 14;13(8):1977. doi: 10.3390/biomedicines13081977.
: Multiple genetic variants have been associated with disease prevalence and outcomes in middle-aged people with metabolic dysfunction-associated fatty liver disease (MAFLD). However, genetic studies in older adults have been lacking. We aimed to understand their clinical relevance in healthy older persons. : A secondary analysis of the ASPREE (ASPirin in Reducing Events in the Elderly) randomized trial involving community-dwelling older adults ≥ 70 years without prior cardiovascular disease events or life-limiting illness at enrolment. The Fatty Liver Index (FLI) was used to identify MAFLD at baseline. We assessed the associations between six previously reported MAFLD-associated genetic variants with prevalent MAFLD at baseline, and the associations of these variants with cardiovascular disease events and all-cause mortality. : A total of 8756 participants with genetic data were stratified according to the FLI, with 3310 having MAFLD at baseline. The follow-up was for a median of 8.4 (IQR 7.3-9.5) years. Variants in two genes ( and ) were associated with prevalent MAFLD ( < 0.05); , , , and were not. , , , , and were associated with major adverse cardiovascular events (MACEs) or mortality in the overall cohort or in participants with MAFLD during the follow-up (all > 0.05). Within the MAFLD group, homozygosity for the rs641738 C > T variant in the gene was associated with a reduced risk of MACEs (HR 0.68 [95% CI 0.48-0.97]), but not all-cause mortality (HR 1.14 [95% CI 0.89-1.47]). This protective association remained significant after adjusting for multiple key covariates (aHR 0.64 [95% CI 0.44-0.92]). The results were similar when using the metabolic dysfunction-associated steatotic liver disease definition rather than MAFLD. : The rs641738 C > T variant in may confer protection against MACEs in older adults with MAFLD, independent of other clinical risk factors. Further validation using external cohorts is needed.
多种基因变异与代谢功能障碍相关脂肪性肝病(MAFLD)中年患者的疾病患病率和预后相关。然而,针对老年人的基因研究一直缺乏。我们旨在了解它们在健康老年人中的临床相关性。:对ASPREE(老年人阿司匹林减少事件)随机试验进行二次分析,该试验纳入了年龄≥70岁、入组时无既往心血管疾病事件或危及生命疾病的社区居住老年人。使用脂肪肝指数(FLI)在基线时识别MAFLD。我们评估了六个先前报道的与MAFLD相关的基因变异与基线时MAFLD患病率之间的关联,以及这些变异与心血管疾病事件和全因死亡率之间的关联。:共有8756名有基因数据的参与者根据FLI进行分层,其中3310人在基线时患有MAFLD。随访时间中位数为8.4(IQR 7.3 - 9.5)年。两个基因(和)中的变异与MAFLD患病率相关(<0.05);,,,和则不相关。,,,,和在随访期间与总体队列或MAFLD患者中的主要不良心血管事件(MACE)或死亡率相关(均>0.05)。在MAFLD组中,基因中rs641738 C>T变异的纯合子与MACE风险降低相关(HR 0.68 [95%CI 0.48 - 0.97]),但与全因死亡率无关(HR 1.14 [95%CI 0.89 - 1.47])。在调整多个关键协变量后,这种保护关联仍然显著(aHR 0.64 [95%CI 0.44 - 0.92])。使用代谢功能障碍相关脂肪性肝病定义而非MAFLD时,结果相似。:基因中的rs641738 C>T变异可能使患有MAFLD的老年人免受MACE影响,独立于其他临床风险因素。需要使用外部队列进行进一步验证。